Emerging and disease-specific mechanisms of hepatic stellate cell activation

Seminars in Liver Disease

Volumn 35, Issue 2, 2015, Pages 107-118

  Wallace, Michael C ^a,b   Friedman, Scott L ^a   Mann, Derek A ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

antifibrotic therapies; chronic viral hepatitis; hepatic fibrosis; hepatic stellate cell; nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA CATENIN; CHOLESTEROL; INTERLEUKIN 33; RETINOL; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GATA 4; WNT PROTEIN;

ALCOHOL LIVER DISEASE; ARTICLE; AUTOPHAGY; CELL ACTIVATION; CELL CYCLE; CHOLESTEROL METABOLISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STELLATE CELL; UNFOLDED PROTEIN RESPONSE; VIRUS HEPATITIS; VITAMIN METABOLISM; APOPTOSIS; HEPATIC STELLATE CELL; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER DISEASES; SIGNAL TRANSDUCTION;

EID: 84929310290     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1550060     Document Type: Article

References (127)

1. Mederacke I., Hsu C. C., Troeger J. S., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun: 2013; 4 2823
2. Iwaisako K., Jiang C., Zhang M., et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A: 2014; 111 32 E3297 E3305
3. Michelotti G. A., Xie G., Swiderska M., et al. Smoothened is a master regulator of adult liver repair. J Clin Invest: 2013; 123 6 2380 2394
4. Wynn T. A. Cellular and molecular mechanisms of fibrosis. J Pathol: 2008; 214 2 199 210
5. Friedman S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev: 2008; 88 1 125 172
6. Hernandez-Gea V., Friedman S. L. Pathogenesis of liver fibrosis. Annu Rev Pathol: 2011; 6 425 456
7. Lee U. E., Friedman S. L. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol: 2011; 25 2 195 206
8. Mann J., Mann D. A. Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev: 2009; 61 7-8 497 512
9. Puche J. E., Saiman Y., Friedman S. L. Hepatic stellate cells and liver fibrosis. Compr Physiol: 2013; 3 4 1473 1492
10. Mann D. A. Epigenetics in liver disease. Hepatology: 2014; 60 4 1418 1425
11. Henderson N. C., Arnold T. D., Katamura Y., et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med: 2013; 19 12 1617 1624
12. Breitkopf K., Godoy P., Ciuclan L., Singer M. V., Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol: 2006; 44 1 57 66
13. Kelly J. D., Haldeman B. A., Grant F. J., et al. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem: 1991; 266 14 8987 8992
14. Wong L., Yamasaki G., Johnson R. J., Friedman S. L. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest: 1994; 94 4 1563 1569
15. Ishikawa K., Mochida S., Mashiba S., et al. Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis. Biochem Biophys Res Commun: 1999; 254 3 587 593
16. Kaur S., Tripathi D., Dongre K., et al. Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J Hepatol: 2012; 57 6 1193 1198
17. Zhao Y., Wang Y., Wang Q., Liu Z., Liu Q., Deng X. Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen-activated protein kinase/cyclooxygenase-2 pathway. Mol Cell Biochem: 2012; 359 1-2 217 223
18. Min H. K., Kapoor A., Fuchs M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab: 2012; 15 5 665 674
19. Arsov T., Larter C. Z., Nolan C. J., et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun: 2006; 342 4 1152 1159
20. Chen A., Tang Y., Davis V., et al. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology: 2013; 57 6 2202 2212
21. Larter C. Z., Yeh M. M., Van Rooyen D. M., et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol: 2009; 24 10 1658 1668
22. Teratani T., Tomita K., Suzuki T., et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology: 2012; 142 1 152 164.e10
23. Tomita K., Teratani T., Suzuki T., et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology: 2014; 59 1 154 169
24. Tomita K., Teratani T., Suzuki T., et al. Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J Hepatol: 2014; 61 1 98 106
25. Van Rooyen D. M., Gan L. T., Yeh M. M., et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol: 2013; 59 1 144 152
26. Van Rooyen D. M., Larter C. Z., Haigh W. G., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology: 2011; 141 4 1393 1403, 1403.e1-1403.e5
27. Henle T. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids: 2005; 29 4 313 322
28. Jiang J. X., Chen X., Fukada H., Serizawa N., Devaraj S., Török N. J. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice. Hepatology: 2013; 58 4 1339 1348
29. Leung C., Herath C. B., Jia Z., et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol: 2014; 60 4 832 838
30. Arndt S., Wacker E., Dorn C., et al. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut: 2014
31. Miura K., Yang L., van Rooijen N., Brenner D. A., Ohnishi H., Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology: 2013; 57 2 577 589
32. Luedde T., Kaplowitz N., Schwabe R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology: 2014; 147 4 765 783.e4
33. Zan Y., Zhang Y., Tien P. Hepatitis B virus e antigen induces activation of rat hepatic stellate cells. Biochem Biophys Res Commun: 2013; 435 3 391 396
34. Bai Q., An J., Wu X., et al. HBV promotes the proliferation of hepatic stellate cells via the PDGF-B/PDGFR-β signaling pathway in vitro. Int J Mol Med: 2012; 30 6 1443 1450
35. Jin Z., Sun R., Wei H., Gao X., Chen Y., Tian Z. Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology: 2011; 53 1 219 229
36. Li J., Qiu S. J., She W. M., et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS ONE: 2012; 7 6 e39307
37. Zhao J., Zhang Z., Luan Y., et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology: 2014; 59 4 1331 1342
38. Florimond A., Chouteau P., Bruscella P., et al. Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication. Gut: 2014
39. Battaglia S., Benzoubir N., Nobilet S., et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS ONE: 2009; 4 2 e4355
40. Benzoubir N., Lejamtel C., Battaglia S., et al. HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment. J Hepatol: 2013; 59 6 1160 1168
41. Presser L. D., McRae S., Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. PLoS ONE: 2013; 8 2 e56367
42. + regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol: 2013; 59 2 229 235
43. Preisser L., Miot C., Le Guillou-Guillemette H., et al. IL-34 and M-CSF are overexpressed in HCV fibrosis and induce pro-fibrotic macrophages which promote collagen synthesis by hepatic stellate cells. Hepatology: 2014
44. Jeong W. I., Park O., Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology: 2008; 134 1 248 258
45. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology: 2011; 141 5 1572 1585
46. Roh Y. S., Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol: 2013; 28 1 01 38 42
47. Álvarez R., Vaz B., Gronemeyer H., de Lera A. R. Functions, therapeutic applications, and synthesis of retinoids and carotenoids. Chem Rev: 2014; 114 1 1 125
48. Radaeva S., Wang L., Radaev S., Jeong W. I., Park O., Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol: 2007; 293 4 G809 G816
49. Yi H. S., Lee Y. S., Byun J. S., et al. Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology: 2014; 60 3 1044 1053
50. Sookoian S., Pirola C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology: 2011; 53 6 1883 1894
51. Valenti L., Al-Serri A., Daly A. K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology: 2010; 51 4 1209 1217
52. Burza M. A., Pirazzi C., Maglio C., et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis: 2012; 44 12 1037 1041
53. Pirazzi C., Valenti L., Motta B. M., et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet: 2014; 23 15 4077 4085
54. Kluwe J., Wongsiriroj N., Troeger J. S., et al. Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis. Gut: 2011; 60 9 1260 1268
55. Nevzorova Y. A., Bangen J. M., Hu W., et al. Cyclin E1 controls proliferation of hepatic stellate cells and is essential for liver fibrogenesis in mice. Hepatology: 2012; 56 3 1140 1149
56. Sekiya Y., Ogawa T., Iizuka M., Yoshizato K., Ikeda K., Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-β-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol: 2011; 226 10 2535 2542
57. Rao H. Y., Wei L., Wang J. H., et al. Inhibitory effect of human interferon-beta-1a on activated rat and human hepatic stellate cells. J Gastroenterol Hepatol: 2010; 25 11 1777 1784
58. Hu W., Nevzorova Y. A., Haas U., et al. Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology: 2014; 59 2 651 660
59. Nevzorova Y. A., Hu W., Cubero F. J., et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta: 2013; 1832 10 1765 1775
60. Reebye V., Sætrom P., Mintz P. J., et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology: 2014; 59 1 216 227
61. Zhang D. Y., Friedman S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology: 2012; 56 2 769 775
62. Czaja M. J., Ding W. X., Donohue T. M. Jr., et al. Functions of autophagy in normal and diseased liver. Autophagy: 2013; 9 8 1131 1158
63. Hernández-Gea V., Ghiassi-Nejad Z., Rozenfeld R., et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology: 2012; 142 4 938 946
64. Tanjore H., Lawson W. E., Blackwell T. S. Endoplasmic reticulum stress as a pro-fibrotic stimulus. Biochim Biophys Acta: 2013; 1832 7 940 947
65. Huang Y., Li X., Wang Y., Wang H., Huang C., Li J. Endoplasmic reticulum stress-induced hepatic stellate cell apoptosis through calcium-mediated JNK/P38 MAPK and Calpain/Caspase-12 pathways. Mol Cell Biochem: 2014; 394 1-2 1 12
66. Hernández-Gea V., Hilscher M., Rozenfeld R., et al. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol: 2013; 59 1 98 104
67. Park H. W., Park H., Ro S. H., et al. Hepatoprotective role of Sestrin2 against chronic ER stress. Nat Commun: 2014; 5 4233
68. Fucho R., Martínez L., Baulies A., et al. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis. J Hepatol: 2014; 61 5 1126 1134
69. Chen J., Han Y., Xu C., Xiao T., Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev: 2014
70. Omenetti A., Choi S., Michelotti G., Diehl A. M. Hedgehog signaling in the liver. J Hepatol: 2011; 54 2 366 373
71. Yang L., Wang Y., Mao H., et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol: 2008; 48 1 98 106
72. Chen Y., Choi S. S., Michelotti G. A., et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology: 2012; 143 5 1319 29.e1, 11
73. Grzelak C. A., Martelotto L. G., Sigglekow N. D., et al. The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury. J Hepatol: 2014; 60 1 143 151
74. Machado M. V., Michelotti G. A., Pereira T. D., et al. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut: 2014
75. Guy C. D., Suzuki A., Abdelmalek M. F., Burchette J. L., Diehl A. M. NASH CRN Treatment response in the PIVENS Trial is associated with decreased Hedgehog pathway activity. Hepatology: 2015; 61 1 98 107
76. Xie G., Karaca G., Swiderska-Syn M., et al. Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology: 2013; 58 5 1801 1813
77. MacDonald B. T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell: 2009; 17 1 9 26
78. Lade A. G., Monga S. P. Beta-catenin signaling in hepatic development and progenitors: which way does the WNT blow? Dev Dyn: 2011; 240 3 486 500
79. Akhmetshina A., Palumbo K., Dees C., et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun: 2012; 3 735
80. Hoshida Y., Nijman S. M., Kobayashi M., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res: 2009; 69 18 7385 7392
81. Myung S. J., Yoon J. H., Gwak G. Y., et al. Wnt signaling enhances the activation and survival of human hepatic stellate cells. FEBS Lett: 2007; 581 16 2954 2958
82. Cheng J. H., She H., Han Y. P., et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol: 2008; 294 1 G39 G49
83. Jiang F., Parsons C. J., Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol: 2006; 45 3 401 409
84. Rashid S. T., Humphries J. D., Byron A., et al. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res: 2012; 11 8 4052 4064
85. Zhai X., Yan K., Fan J., et al. The β-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br J Pharmacol: 2013; 169 1 197 212
86. Yin X., Yi H., Wu W., Shu J., Wu X., Yu L. R-spondin2 activates hepatic stellate cells and promotes liver fibrosis. Dig Dis Sci: 2014; 59 10 2452 2461
87. Voronkov A., Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des: 2013; 19 4 634 664
88. Delgado I., Carrasco M., Cano E., et al. GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice. Hepatology: 2014; 59 6 2358 2370
89. Patankar J. V., Chandak P. G., Obrowsky S., et al. Loss of intestinal GATA4 prevents diet-induced obesity and promotes insulin sensitivity in mice. Am J Physiol Endocrinol Metab: 2011; 300 3 E478 E488
90. Patankar J. V., Obrowsky S., Doddapattar P., et al. Intestinal GATA4 deficiency protects from diet-induced hepatic steatosis. J Hepatol: 2012; 57 5 1061 1068
91. Zheng R., Rebolledo-Jaramillo B., Zong Y., et al. Function of GATA factors in the adult mouse liver. PLoS ONE: 2013; 8 12 e83723
92. Lopez-Sanchez I., Dunkel Y., Roh Y. S., et al. GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis. Nat Commun: 2014; 5 4451
93. Ward P. S., Thompson C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell: 2012; 21 3 297 308
94. Beaven S. W., Wroblewski K., Wang J., et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology: 2011; 140 3 1052 1062
95. Hazra S., Xiong S., Wang J., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem: 2004; 279 12 11392 11401
96. Verbeke L., Farre R., Trebicka J., et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology: 2014; 59 6 2286 2298
97. Fiorucci S., Antonelli E., Rizzo G., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology: 2004; 127 5 1497 1512
98. Calkin A. C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol: 2012; 13 4 213 224
99. Kong B., Luyendyk J. P., Tawfik O., Guo G. L. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther: 2009; 328 1 116 122
100. Li T., Eheim A. L., Klein S., et al. Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology: 2014; 59 6 2383 2396
101. Kojetin D. J., Burris T. P. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov: 2014; 13 3 197 216
102. Ruano E. G., Canivell S., Vieira E. REV-ERB ALPHA polymorphism is associated with obesity in the Spanish obese male population. PLoS ONE: 2014; 9 8 e104065
103. Marvie P., Lisbonne M., L'helgoualc'h A., et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med: 2010; 14 (6B): 1726 1739
104. McHedlidze T., Waldner M., Zopf S., et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity: 2013; 39 2 357 371
105. Zeybel M., Mann D. A., Mann J. Epigenetic modifications as new targets for liver disease therapies. J Hepatol: 2013; 59 6 1349 1353
106. Tian W., Hao C., Fan Z., et al. Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells. J Hepatol: 2015; 62 1 165 174
107. Small E. M., Thatcher J. E., Sutherland L. B., et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res: 2010; 107 2 294 304
108. Luchsinger L. L., Patenaude C. A., Smith B. D., Layne M. D. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts. J Biol Chem: 2011; 286 51 44116 44125
109. Hampl V., Martin C., Aigner A., et al. Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med: 2013; 5 9 1367 1382
110. Perugorria M. J., Wilson C. L., Zeybel M., et al. Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology: 2012; 56 3 1129 1139
111. Xin X., Zhang Y., Liu X., et al. MicroRNA in hepatic fibrosis and cirrhosis. Front Biosci (Landmark Ed): 2014; 19 1418 1424
112. Roderburg C., Urban G. W., Bettermann K., et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology: 2011; 53 1 209 218
113. Ramdas V., McBride M., Denby L., Baker A. H. Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. Am J Pathol: 2013; 183 6 1885 1896
114. Zhang Y., Huang X. R., Wei L. H., Chung A. C., Yu C. M., Lan H. Y. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther: 2014; 22 5 974 985
115. Parker M. W., Rossi D., Peterson M., et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest: 2014; 124 4 1622 1635
116. Montgomery R. L., Yu G., Latimer P. A., et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med: 2014; 6 10 1347 1356
117. Seok J., Warren H. S., Cuenca A. G., et al. Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A: 2013; 110 9 3507 3512
118. Takao K., Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci U S A: 2015; 112 4 1167 1172
119. Westra I. M., Oosterhuis D., Groothuis G. M., Olinga P. The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS ONE: 2014; 9 4 e95462
120. Ikegami T., Maehara Y. Transplantation: 3D printing of the liver in living donor liver transplantation. Nat Rev Gastroenterol Hepatol: 2013; 10 12 697 698
121. Wu Q., Gao D., Wei J., et al. Development of a novel multi-layer microfluidic device towards characterization of drug metabolism and cytotoxicity for drug screening. Chem Commun (Camb): 2014; 50 21 2762 2764
122. Sirota M., Dudley J. T., Kim J., et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med: 2011; 3 96 96ra77
123. Jahchan N. S., Dudley J. T., Mazur P. K., et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov: 2013; 3 12 1364 1377
124. Dudley J. T., Sirota M., Shenoy M., et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med: 2011; 3 96 96ra76
125. Liu Y. L., Reeves H. L., Burt A. D., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun: 2014; 5 4309
126. Puche J. E., Lee Y. A., Jiao J., et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology: 2013; 57 1 339 350
127. Arabpour M., Poelstra K., Helfrich W., Bremer E., Haisma H. J. Targeted elimination of activated Hepatic Stellate Cells by an anti-EGF-receptor scFv-sTRAIL fusion protein. J Gene Med: 2014